rs113978340 - TCAIM - C3orf86P
Magnitude 2.2 · 1 study on file
Reported associations
-
Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors - Unknown journal (n.d.) · Unknown authors · PubMed 39543288
ABSTRACT: Tinnitus is a common sensorineural complication that can occur de novo or after cancer treatments involving cisplatin or radiotherapy. Considering the heterogeneous etiology and pathophysiology of tinnitus, the extent to which shared genetic risk factors contribute to de novo tinnitus and cancer treatment-induced tinnitus is not clear. Here we report a GWAS for de novo tinnitus using the UK Biobank cohort with nine loci showing significantly associated variants (p < 5 × 10-8). To our knowledge, significant associations in four of these loci are novel, represented by rs7336872, rs115125870, rs1532898 and rs2537, with UBAC2, NUDT9, TGM4 and MPP2 as their nearest protein coding genes, respectively. Through quantitative comparison of results from GWAS of de novo tinnitus w
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Discuss tinnitus risk and hearing health Moderate
Genetic predisposition to tinnitus identified; may warrant clinical monitoring and preventive counseling
Bring up during annual checkup or if tinnitus symptoms develop
Lifestyle
-
Limit loud noise exposure Moderate
Genetic predisposition to tinnitus may increase sensitivity to noise-induced damage
Wear hearing protection in loud environments; keep headphone volume moderate
Screening
-
Baseline hearing assessment and audiometry Moderate
Genetic variants associated with tinnitus risk may indicate benefit from early audiological evaluation
Schedule audiometry; repeat every 3-5 years